Source link : https://www.newshealth.biz/health-news/no-clear-winner-in-sglt2-showdown-for-cardiovascular-disease/
Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable risks of hospitalization for acute MI/ischemic stroke and heart failure hospitalization on these drugs. Only the 5-mg dose of dapagliflozin, not recommended for cardiovascular risk reduction, showed a reduced benefit. Individual SGLT2 […]
Author : News Health
Publish date : 2025-01-22 20:03:17
Copyright for syndicated content belongs to the linked Source.